Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer

• Published in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association Vol. 19; no. 1; pp. 234 - 244
• Main Authors: Wang, Jinwan, Xu, Ruihua, Li, Jian, Bai, Yuxian, Liu, Tianshu, Jiao, Shunchang, Dai, Guanghai, Xu, Jianming, Liu, Yunpeng, Fan, Nanfeng, Shu, Yongqian, Ba, Yi, Ma, Dong, Qin, Shukui, Zheng, Leizhen, Chen, Weichang, Shen, Lin
• Format: Journal Article
• Language: English
• Published: Tokyo Springer Japan 01.01.2016; Springer Nature B.V
• Subjects: Abdominal Surgery; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cancer Research; Cisplatin - administration & dosage; Cisplatin - adverse effects; Female; Fluorouracil - administration & dosage; Fluorouracil - adverse effects; Gastric cancer; Gastroenterology; Humans; Male; Medicine; Medicine & Public Health; Middle Aged; Neoplasm Recurrence, Local; Oncology; Original; Original Article; Stomach Neoplasms - drug therapy; Stomach Neoplasms - mortality; Stomach Neoplasms - pathology; Surgical Oncology; Survival Rate; Taxoids - administration & dosage; Taxoids - adverse effects; Treatment Outcome; Young Adult; Safety; Overall survival; Advanced gastric cancer; Progression-free survival; Modified docetaxel and cisplatin plus fluorouracil regimen

Background The V325 study showed that docetaxel, cisplatin, and fluorouracil (DCF) prolonged overall survival (OS) of patients with advanced gastric cancer, but with a high incidence of dose-limiting toxicities. We investigated the efficacy and safety of a modified DCF (mDCF) regimen for Chinese pat...